Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 12Small Cell Lung Carcinoma 11Fallopian Tube Neoplasms 9Neuroblastoma 6Neoplasm Metastasis 3Lung Neoplasms 3Ganglioneuroblastoma 3Carcinoma, Ovarian Epithelial 3Uterine Cervical Neoplasms 2Sarcoma, Ewing 2Rhabdoid Tumor 2Recurrence 2Leukemia, Myeloid, Acute 2Glioma 2Central Nervous System Neoplasms 2Wilms Tumor 1Thrombocythemia, Essential 1SCLC 1Primary Myelofibrosis 1Polycythemia Vera 1Pleuropulmonary blastoma 1Peritoneal Neoplasms 1Pediatric Brain Tumor 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms 1Myelodysplastic-Myeloproliferative Diseases 1Lymphoma, Follicular 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1

Interventions

Watchful Waiting 1Vincristine 1Topotecan 1Specimen Handling 1Razoxane 1Observation 1Magnetic Resonance Spectroscopy 1Ifosfamide 1High-Energy Shock Waves 1Doxorubicin 1Dexrazoxane 1Dactinomycin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pleuropulmonary blastoma × Topotecan × 90 days × Clear all
NCT06647953 2026-05-05

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

Children's Oncology Group

Phase 3 Recruiting
110 enrolled

Pleuropulmonary blastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡